Patrick S Plum
Overview
Explore the profile of Patrick S Plum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schiffmann L, Plum P, Fuchs H, Babic B, Bruns C, Schmidt T
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572905
Esophageal cancer is among the top ten most deadly cancers worldwide with adenocarcinomas of the esophagus showing increasing incidences over the last years. The prognosis is determined by tumor stage...
12.
Plum P, Quaas A, Alakus H, Bruns C
Chirurg
. 2021 Jul;
92(11):981-985.
PMID: 34287671
Background: In the recent past tumors of the upper gastrointestinal (GI) tract, e.g. esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC) and gastric adenocarcinoma, have been increasingly characterized by molecular...
13.
Zhou C, Wang Z, Li J, Wu X, Fan N, Li D, et al.
Cancers (Basel)
. 2021 Jun;
13(10).
PMID: 34065695
Esophageal adenocarcinoma (EAC) is one of the most lethal malignancies, and limits promising treatments. AKR1C3 represents a therapeutic target to combat the resistance in many cancers. However, the molecular mechanism...
14.
Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, et al.
Gut
. 2021 Jan;
71(1):185-193.
PMID: 33431577
Objective: Intrahepatic cholangiocarcinoma (ICC)-a rare liver malignancy with limited therapeutic options-is characterised by aggressive progression, desmoplasia and vascular abnormalities. The aim of this study was to determine the role of...
15.
Zhou C, Fan N, Liu F, Fang N, Plum P, Thieme R, et al.
Cells
. 2020 Jun;
9(6).
PMID: 32560537
Esophageal cancer (EC) is an aggressive form of cancer, including squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) as two predominant histological subtypes. Accumulating evidence supports the existence of cancer stem...
16.
Kramer M, Plum P, Velazquez Camacho O, Folz-Donahue K, Thelen M, Garcia-Marquez I, et al.
Mol Oncol
. 2020 Apr;
14(6):1170-1184.
PMID: 32255255
Single-cell transcriptomics have revolutionized our understanding of the cell composition of tumors and allowed us to identify new subtypes of cells. Despite rapid technological advancements, single-cell analysis remains resource-intense hampering...
17.
Hescheler D, Plum P, Zander T, Quaas A, Korenkov M, Gassa A, et al.
Gastric Cancer
. 2020 Feb;
23(4):627-638.
PMID: 32107691
Background: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for...
18.
Schiffmann L, Gobel H, Loser H, Schorn F, Werthenbach J, Fuchs H, et al.
BMC Cancer
. 2019 Jun;
19(1):531.
PMID: 31151416
Background: Molecular markers predicting survival in esophageal adenocarcinoma (EAC) are rare. Specifically, in favorable oncologic situations, e.g. nodal negativity or major neoadjuvant therapy response, there is a lack of additional...
19.
Berlth F, Plum P, Chon S, Gutschow C, Bollschweiler E, Holscher A
Surg Endosc
. 2018 Jun;
32(12):4957-4965.
PMID: 29931451
Background: The impact of total minimally invasive esophagectomy (MIE) on early postoperative outcome and patient's survival is a matter of recent discussion. Methods: We performed a 1:2 propensity score-matched comparison...
20.
Chiapponi C, Berlth F, Plum P, Betzler C, Stippel D, Popp F, et al.
Visc Med
. 2017 Jun;
33(1):31-34.
PMID: 28612014
Background: In the present study we review and discuss the current evidence and suggest how to proceed in the management of oligometastatic disease in upper gastrointestinal cancer. Methods: An electronic...